In a world where both the prevalence of diabetes and resistance to antibacterial drugs are rapidly increasing, the emerging diabetic foot infection (DFI), which is caused by resistant and multi-resistant strains, is considered an emergency situation both from a clinical and from an organizative point of view. Both gram-positive and gram-negative strains show an increasing incidence of antibiotic resistance and both the morbidity and mortality of patients with DFI sustained by resistant strains are significantly higher than those of non-resistant DFIs. Besides well-known resistance to penicillin in gram-positive cocci, the new form of enzymatic resistance in gram-negative rods: extended-spectrum beta lactamases, ampicillinase-C and carbapenemase production, not to forget multi-drug resistance, are all creating a new and frightening scenario in DFI, to which only a paradigm shift in treatment strategies, like the atibacterial therapy stewardship programs, may give positive answers in the near future. © 2018 S. Karger AG, Basel.

Resistant Infections in the Diabetic Foot: A Frightening Scenario

Tascini C
2017-01-01

Abstract

In a world where both the prevalence of diabetes and resistance to antibacterial drugs are rapidly increasing, the emerging diabetic foot infection (DFI), which is caused by resistant and multi-resistant strains, is considered an emergency situation both from a clinical and from an organizative point of view. Both gram-positive and gram-negative strains show an increasing incidence of antibiotic resistance and both the morbidity and mortality of patients with DFI sustained by resistant strains are significantly higher than those of non-resistant DFIs. Besides well-known resistance to penicillin in gram-positive cocci, the new form of enzymatic resistance in gram-negative rods: extended-spectrum beta lactamases, ampicillinase-C and carbapenemase production, not to forget multi-drug resistance, are all creating a new and frightening scenario in DFI, to which only a paradigm shift in treatment strategies, like the atibacterial therapy stewardship programs, may give positive answers in the near future. © 2018 S. Karger AG, Basel.
2017
9783318061444
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1198767
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact